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these unexpected results. We are also questioning about
differences in the PBmedication among the 11 participating
countries.
After investigating the reasons for the very low numbers
of PB prescription, we strongly suggest a separate analysis
of the patients on the basis of the PB medications and the
serum phosphate level to understand the association of
these parameters with the outcomes. Apart from some par-
ticular dialysis schedule including long and/or daily strat-
egies, phosphataemia remains an important marker of
nutrition in cases of conventional HD. The use of PBs could
be associated with a better outcome when associated with a
higher protein intake, but this remains a speculation.
We encourage the ARO investigators to provide more
observational data from European countries to improve
our understanding of the association between mineral me-
tabolism disorders, their treatments and outcomes.
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Reply
Jean and Vanel raise some interesting questions about the
management of dialysis patients in Europe and the associ-
ation between phosphorous and mortality, especially when
considering the use of phosphate binders. In the ARO
population, the majority of patients (>80% in all countries)
have three dialysis sessions per week, with the median dur-
ation of each session being 4 h. Unfortunately, ARO does
not contain data allowing us to estimate dietary phosphate
intake. We cannot fully exclude underreporting of phosphate
binder use in some countries. Moreover, dosing equivalence
between different phosphate binders used in this cohort,
which is really difficult to establish, prevented us from
looking at a dose-dependent effect. However, we found no
relationship between the prevalence of phosphate binder use
and phosphate levels at baseline.
In our population, we observed a significant interaction
between phosphate level, phosphate binder use and mortality
(P = 0.02). As can be seen in Table 1, this interaction is being
driven by the lack of an association between low phosphate
levels and mortality in those treated with a phosphate binder
compared to those untreated.
In principle, this observation is consistent with the data
of Isakova et al. [1], who noted a reduced mortality in
haemodialysis patients treated with a phosphate binder.
However, in that study, most of the benefit was observed
in patients with high phosphate levels, whereas in our
study patients treated to low phosphate levels appeared
to benefit most from a phosphate binder.
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Is there a link between thrombotic thrombocytopenic
purpura and anti-glomerular basement membrane
disease?
Sir,
We read with interest the article by Torok et al. [1]. They
reported a 43-year-old Caucasian male who had developed
thrombotic thrombocytopenic purpura (TTP) followed by
anti-glomerular basement membrane (anti-GBM) disease
Table 1. Association between phosphate levels and mortality in the ARO
population according to whether or not a participant is taking a phosphate
binder at baseline
Phosphate
(mmol/L)
Adjusted HR (95% CI)a
Not taking
phosphate binders
Taking phosphate
binders
<1.13 1.29 (1.08–1.55) 1.00 (0.75–1.34)
1.13–1.78 1 1
>1.78 1.32 (1.07–1.64) 1.33 (1.04–1.71)
aAdjusted for demographics (age, gender, country, body mass indexBMI,
smoking status), medical history (chronic kidney disease aetiology, history
of diabetes, history of cardiovascular disease (CVD), history of Cancer),
dialysis parameters (vintage, vascular access type, Kt/V, blood flow),
markers of inflammation (serum albumin, C-reactive protein), CVD
medications (antihypertensive drugs, ACE inhibitors, oral anticoagulants,
anti-aggregants), vitamin D use and other lab parameters (PTH, calcium,
haemoglobinHb, ferritin, cholesterol, blood leucocytes) and miscellaneous
(hospitalization, change in vascular access type).
2058 Nephrology Dialysis Transplantation (2011)
 at Y
O
N
SEI U
N
IV
ERSITY
 M
ED
ICA
L LIBRA
RY
 on N
ovem
ber 24, 2013
http://ndt.oxfordjournals.org/
D
ow
nloaded from
 
[1]. They described that multiple autoimmune diseases
could occur in the same patient as the theory of a ‘mosaic
of autoimmunity’ but did not suggest the possible mecha-
nisms [1].
Although not extensively studied yet, we speculate
that the helper T (Th) cell-associated cytokine, interleukin
(IL)-12, might be involved in the common pathogenesis
between the two diseases [2,3]. Takatsuka et al. [2] showed
that the patients with thrombotic microangiopathy had a sig-
nificant increase of IL-12 at the time of leukocyte recovery
after bone marrow transplantation (BMT) (P < 0.05), while
none of the patients without microangiopathy showed an
increase of IL-12. Kakishita also reported that TTP and
haemolytic uraemic syndrome (HUS) after BMT might
be predicted at an early stage by determining any increase
in plasma IL-12 at the time of leukocyte recovery [3], sug-
gesting the possibility that TTP might be related to inflam-
mation or autoimmunity.
In addition, Kalluri et al. [4] developed a new mouse
model of human anti-GBM disease, in which crescentic
glomerulonephritis and lung haemorrhage were associated
with the emergence of an IL-12/Th1-like T-cell phenotype.
Conversely, Kitching et al. [5] demonstrated that IL-12p40−/−
knockout mice were protected from renal injury in an experi-
mental model of autoimmune anti-GBMglomerulonephritis.
Therefore, there is a possibility that IL-12 might play an
important role in the development of both TTP and anti-
GBM disease and it would be interesting to measure IL-12
during the course of the disease in the patient of Torok et
al. [1].
However, further studies are necessary to elucidate
whether IL-12 is elevated in all kinds of TTP or HUS
and whether it might also play an important role in the de-
velopment of human anti-GBM disease. The relationship
between IL-12 levels and the degree of ADAMTS13 defi-
ciency or the titres of anti-GBM antibody should be further
evaluated in the future.
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Reply
Sir,
Shin et al. letter lends an important perspective on a critical
topic. We previously reported the simultaneous presentation
of thrombotic thrombocytopenic purpura (TTP) and Good-
pasture’s disease in the same patient. We agree completely
that the pathogenic mechanism of TTP and Goodpasture’s
disease was not identified in our case. We speculated the
‘mosaic of autoimmunity’ theory as an explanation of this
association based on the accumulating evidence of the auto-
immune nature of TTP [1] and Goodpasture’s disease.
However, transplant associated thrombotic microangio-
pathy (TA-TMA) is a different entity from TTP [2]. Patho-
logically, the thrombi in TA-TMA contain both fibrin and
von Willebrand Factor, whereas in TTP, the thrombi consist
mainly of platelets [3]. Suggesting that these diseases
are different, this makes us believe that the underlying
pathologic mechanisms might also be different. Besides,
TA-TMA can be related to other causes, like Graft Versus
Host Disease, to immunosuppressive medications side-
effects and to viral infections which all can mimic TTP
[4]. Therefore, high IL-12 levels preceding TA-TMAmight
not exactly fit TTP. Nevertheless, we still feel that it is inter-
esting to extend this observation to TTP, and further studies
are thus needed. Concerning Goodpasture’s disease, the
interest has been shifted to IL-23 byKitching et al., the same
group who reported the protective role of IL-12 in the ex-
perimental knockout mouse model against the development
of the disease [5]. In our case report, we did not have base-
line IL-12 levels before or during the disease activity, which
makes it impossible to confirm or dispute the relation
between IL-12 and these entities.
We share the conclusion of Kim et al. that further research
focusing on the possible autoimmune mechanisms in TTP
and anti-GBM disease, specifically the relation with IL-12,
is needed. What we know about these intriguing entities is
less than what we do not know.
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